Related Experiment Video
Updated: Jun 20, 2026

Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
Published on: June 20, 2015
[Usefulness of metformin in diabetes-related bone disease]
1Internal Medicine 1, Shimane University Faculty of Medicine.
Abstract:
Accumulative evidence shows that type 2 diabetes patients have high fracture rate in spite of the absence of bone mineral density (BMD) reduction. The etiology and treatment of diabetes-related bone disease have recently attracted widespread attention. Recent epidemiologic studies have shown that the fracture rate was decreased in patients treated with metformin, one of the anti-hyperglycemic agents by improving insulin resistance. Several studies have indicated that metformin directly stimulated the differentiation of osteoblastic cells, and that metformin reversed deleterious effects of advanced glycation end products on these cells. Further longitudinal studies are needed to clarify the effects of metformin on BMD, bone turnover markers, and fracture risks in type 2 diabetes.
More Related Videos
Related Concept Videos
Oral Hypoglycemic Agents: Biguanides and Glitazones
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are typically...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
Dipeptidyl Peptidase 4 Inhibitors
Essential Minerals for Bone Health
Calcium and Phosphorus
Calcium is a critical component of bones, especially in the form of calcium phosphate and calcium carbonate. Since the body cannot make calcium, it must be obtained from the diet. However, calcium cannot be absorbed from the small intestine without...
Diabetes: Management and Pharmacotherapy
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

